VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 264 filers reported holding VAXCYTE INC in Q2 2024. The put-call ratio across all filers is 0.45 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $56,877,152 | +11.8% | 753,240 | +1.1% | 4.39% | -17.6% |
| Q1 2024 | $50,890,950 | -19.2% | 745,000 | -25.7% | 5.33% | -23.6% |
| Q4 2023 | $62,951,160 | -5.2% | 1,002,407 | -23.0% | 6.97% | -35.8% |
| Q3 2023 | $66,396,709 | +2.3% | 1,302,407 | +0.2% | 10.86% | +21.6% |
| Q2 2023 | $64,922,000 | +42.4% | 1,300,000 | +6.8% | 8.93% | +51.7% |
| Q1 2023 | $45,605,064 | +35.2% | 1,216,784 | +73.0% | 5.89% | +13.8% |
| Q4 2022 | $33,729,996 | +101.2% | 703,441 | +0.7% | 5.17% | +46.4% |
| Q3 2022 | $16,767,000 | +6.5% | 698,638 | -3.5% | 3.53% | -12.2% |
| Q2 2022 | $15,749,000 | +12.5% | 723,781 | +24.9% | 4.02% | -11.4% |
| Q1 2022 | $13,998,000 | +178.2% | 579,640 | +174.1% | 4.54% | +68.9% |
| Q4 2021 | $5,031,000 | – | 211,483 | – | 2.69% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $59,882,148 | 46.04% |
| Darwin Global Management, Ltd. | 2,080,946 | $163,916,116 | 19.07% |
| RA Capital Management | 8,203,754 | $619,465,465 | 8.19% |
| ACUTA CAPITAL PARTNERS, LLC | 110,400 | $8,336,304 | 7.02% |
| COMMODORE CAPITAL LP | 1,305,000 | $98,540,550 | 6.73% |
| Saturn V Capital Management LP | 215,680 | $16,285,997 | 6.15% |
| Cormorant Asset Management, LP | 1,100,000 | $83,061,000 | 4.80% |
| Kynam Capital Management, LP | 753,240 | $56,877,152 | 4.39% |
| Novo Holdings A/S | 950,000 | $71,734,500 | 4.16% |
| Frazier Life Sciences Management, L.P. | 1,039,405 | $78,485,472 | 3.67% |